Cardiologists, Cardiovascular Nurses, Endocrinologists, Family Practitioners, Internists, Lipidologists, Lipid Specialists, Nephrologists, Nurse Practitioners, Pharmacists and Dietitians, PhDs, physicians assistants, Primary Care Physicians
Hypertriglyceridemia
1. | Describe normal triglyceride physiology and pathophysiology | 2. | Identify genetic and acquired disorders associated with hypertriglyceridemia |
3. | Recognize the value of non-HDL-C in the diagnosis and treatment of triglyceride disorders | 4. | Define treatment goals for patients with hypertriglyceridemia based on the most currently available guidelines, integrating results of clinical trials into comprehensive management strategies |
5. | Describe pharmacologic and non-pharmacologic (diet and lifestyle modification) therapies used for the treatment of dyslipidemia and the management of hypertriglyceridemia | 6. | Identify the relationship between serum triglyceride levels and risk for atherosclerotic cardiovascular disease |
7. | Describe gender and ethnic differences in the clinical presentation of hypertriglyceridemia | 8. | Define diagnostic criteria for type II diabetes and the association of insulin resistance to the development of dyslipidemia and cardiovascular disease |
9. | Discuss the potential benefits of gastric bypass surgery in patients who are obese with other co-morbid conditions | 10. | Discuss the management of hypertriglyceridemia in patients with HIV |
1. | Describe normal triglyceride physiology and pathophysiology |
2. | Identify genetic and acquired disorders associated with hypertriglyceridemia |
3. | Recognize the value of non-HDL-C in the diagnosis and treatment of triglyceride disorders |
4. | Define treatment goals for patients with hypertriglyceridemia based on the most currently available guidelines, integrating results of clinical trials into comprehensive management strategies |
5. | Describe pharmacologic and non-pharmacologic (diet and lifestyle modification) therapies used for the treatment of dyslipidemia and the management of hypertriglyceridemia |
6. | Identify the relationship between serum triglyceride levels and risk for atherosclerotic cardiovascular disease |
7. | Describe gender and ethnic differences in the clinical presentation of hypertriglyceridemia |
8. | Define diagnostic criteria for type II diabetes and the association of insulin resistance to the development of dyslipidemia and cardiovascular disease |
9. | Discuss the potential benefits of gastric bypass surgery in patients who are obese with other co-morbid conditions |
10. | Discuss the management of hypertriglyceridemia in patients with HIV |
FACULTY DISCLOSURES | ||
NAME | RELATIONSHIP | COMPANY |
Karen Aspry, MD | Consultant | Merck & Co., Inc. |
Contracted Research | Merck & Co., Inc. | |
Eliot Brinton, MD | Consultant | Aegerion, Amarin, Amgen, Arisaph, AstraZeneca, Atherotech Inc., Eli Lilly & Co., Essentialis, Genzyme, Janssen Pharmaceuticals, Inc., Kowa Pharmaceuticals, Merck & Co., Inc., Novartis, Sanofi-aventis, Takeda Pharmaceuticals |
Contracted Research | Amarin, Health Diagnostic Laboratory, Inc., | |
Speaker | Aegerion, Amarin, AstraZeneca, Daiichi Sankyo, Inc., Genzyme, Janssen Pharmaceuticals, Inc., Kowa Pharmaceuticals, Merck & Co., Inc., Takeda Pharmaceuticals | |
Kevin Maki, PhD | Advisory Board | Amarin, Omthera/ AstraZeneca, Pharmavite, LLC, Sancilio and Company, Inc., Trygg Pharmaceuticals |
Consultant | Abbott/ AbbVie Laboratories, Omthera/ AstraZeneca, Pharmavite, LLC, Trygg Pharmaceuticals | |
Contracted Research | Abbott/ AbbVie Laboratories, DSM, Omthera/ AstraZeneca, Pharmavite, LLC, Trygg Pharmaceuticals | |
Speaker | Amarin | |
Carl Orringer, MD | Consultant | Merck & Co., Inc. |
James Underberg, MD | Advisory Board | GlaxoSmithKline, Kowa Pharmaceuticals, Merck & Co., Inc. |
Consultant | Aegerion, Amarin, AstraZeneca, Eli Lilly & Co., Genzyme, LipoScience, Inc., Novartis | |
Contracted Research | Genzyme | |
Speakers Bureau | Daiichi Sankyo, Inc., GlaxoSmithKline, Kowa Pharmaceuticals, LipoScience, Inc., Merck & Co., Inc., Novartis | |
Robert Wild, MD, PhD, MPH | Consultant | Atherotech |
Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |